ロード中...
Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients
Abstract Aim To independently assess the impact of mandatory testing using an extended DPYD variant panel (ToxNav®) and consequent dose adjustment of Capecitabine/5-FU on recorded quantitative toxicity, symptoms of depression, and hospital costs. Methods We used propensity score matching (PSM) to ma...
保存先:
| 主要な著者: | , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2022-04-01
|
| シリーズ: | BMC Cancer |
| オンライン･アクセス: | https://doi.org/10.1186/s12885-022-09576-3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|